Contents

Search

non-HDL cholesterol in serum

Total Cholesterol - HDL-cholesterol Reference interval: - in statin-treated patients, target non-HDL cholesterol of < 120 mg/dL [4] Clinical significance: - see lipid panel - risk of major cardiovascular events associated with increased non-HDL cholesterol > with LDL cholesterol &/or serum apolipoprotein B [2] - high serum non-HDL cholesterol associated with risk for 1st cardiovascular event - treating high levels early in life can reduce risk [3]

Related

lipid panel (fasting lipid panel, FLP)

General

general chemistry test

References

  1. Journal Watch 24(19):152, 2004 Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review. PMID: 15358046
  2. Boekholdt SM et al Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins JAMA. 2012;307(12):1302-1309 PMID: 22453571 http://jama.ama-assn.org/content/307/12/1302.short
  3. Brunner FJ et al Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. Dec 3, 2019 PMID: 31810609 Free Article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32519-X/fulltext - Robinson JG The next treatment paradigm in cardiovascular prevention? Lancet. Dec 3, 2019 PMID: 31810608 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32949-6/fulltext
  4. Wendling P ApoB May Better Predict Mortality Risk in Statin-Treated Patients. Medscape - Mar 17, 2021. https://www.medscape.com/viewarticle/947631 - Lindhardt Johannesen CD, Mortensen MB, Langsted A, Nordestgaard BG, Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021. 77(11):1439-1450 PMID: 33736827 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.027 - Stone NJ, Lloyd-Jones D Tracking Residual Risk: Time for a Change? J Am Coll Cardiol 2021. 77(11):1451-1453 PMID: 33736828 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.035